Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial-Reference-Cited by-同舟云学术

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Published:2014-12-31 Issue: Volume: Page:dc141850
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Udell Jacob A.,Bhatt Deepak L.,Braunwald Eugene,Cavender Matthew A.,Mosenzon Ofri,Steg Ph. Gabriel,Davidson Jaime A.,Nicolau Jose C.,Corbalan Ramon,Hirshberg Boaz,Frederich Robert,Im KyungAh,Umez-Eronini Amarachi A.,He Ping,McGuire Darren K.,Leiter Lawrence A.,Raz Itamar,Scirica Benjamin M.,

Funder

AstraZeneca

Bristol-Myers Squibb

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets;Diabetes, Metabolic Syndrome and Obesity;2024-06

2. Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials;Diabetes, Metabolic Syndrome and Obesity;2024-03

3. Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis;Frontiers in Pharmacology;2023-11-17

4. Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model;European Journal of Pharmaceutical Sciences;2023-10

5. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes;Diabetology & Metabolic Syndrome;2023-07-19